101184-73-0

Basic information

• Product Name: 2-(4-Bromophenyl)-2-methylpropanenitrile
• Synonyms: 2-(4-BROMOPHENYL)-2-METHYLPROPANENITRILE;2-(4-BROMOPHENYL)-2-METHYLPROPIONITRILE;4-Bromo-alpha,alpha-dimethylbenzeneacetonitrile;P-Bromo a,a-Dimethyl Phenyl Acetonitrile;2-(4-Bromophenyl)-2-methylpropanenitrile 98%;ALPHA,ALPHA-DIMETHYL-4-BROMOPHENYLACETONITRILE;α,α-Dimethyl 4-bromophenylacetonitrile;2-(4-Bromophenyl)-2-methylpropanenitrile-2
• CAS NO: 101184-73-0
• Molecular Formula: C₁₀H₁₀BrN
• Molecular Weight: 224.1
• Product Categories: blocks;Bromides;Carboxes
• Mol File: 101184-73-0.mol

Chemical Properties

• Melting Point: 110-113
• Boiling Point: 299.8 °C at 760 mmHg
• Flash Point: 135.1 °C
• Appearance: /
• Density: 1.352g/cm³
• Vapor Pressure: 0.00117mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: Keep Cold
• CAS DataBase Reference: 2-(4-Bromophenyl)-2-methylpropanenitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Bromophenyl)-2-methylpropanenitrile(101184-73-0)
• EPA Substance Registry System: 2-(4-Bromophenyl)-2-methylpropanenitrile(101184-73-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-51
• Hazardous Substances Data: 101184-73-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Bromophenyl)-2-methylpropanenitrile is used as an intermediate in the synthesis of drugs for its role in creating sedative, hypnotic, and anxiolytic properties. It is crucial in the development of medications that address anxiety, sleep disorders, and other conditions requiring calming effects.
Used in Organic Synthesis:
2-(4-Bromophenyl)-2-methylpropanenitrile is used as a building block in the production of various other organic compounds, contributing to the creation of a wide range of chemical products and materials. Its versatility in organic synthesis makes it a valuable component in the chemical industry.

InChI:InChI=1/C10H10BrN/c1-10(2,7-12)8-3-5-9(11)6-4-8/h3-6H,1-2H3

Upstream product

• 16532-79-9 4-Bromophenylacetonitrile 
• 74-88-4 methyl iodide 
• 119072-55-8 tert-butylisonitrile 
• 586-61-8 4-iso-propylbromobenzene 

Downstream Products

• 169032-17-1 2-[4-(4-chloro-butyryl)-phenyl]-2-methyl-propionitrile 
• 83799-24-0 fexofenadine 
• 264602-70-2 2-(4-bromophenyl)-2-methylpropan-1-amine 
• 1236409-63-4 ethyl 3-(4-(2-cyanopropan-2-yl)phenylamino)propanoate 
• 1784426-29-4 7-bromo-4,4-dimethyl-3,4-dihydroisoquinolin-1(2H)-one 
• 115279-57-7 2-(4-aminophenyl)-2-methylpropionitrile 
• 1082066-30-5 2-methyl-2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-propionitrile 
• 1360549-57-0 5-(4-{1-methyl-1-[5-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]oxadiazol-3-yl]ethyl}phenyl)pyrimidin-2-ylamine 
• 1360552-06-2 2-[4-(2-aminopyrimidin-5-yl)phenyl]-N-hydroxyisobutyramidine 
• 1309580-85-5 ethyl 4-(1-cyano-1-methyl-ethyl)benzoate 
• 129488-74-0 4-(1-cyano-1-methylethyl)benzoic acid 
• 850568-67-1 [4-(1-cyano-1-methylethyl)phenyl]boronic acid 
• 1431616-21-5 6-(4-(2-cyanopropan-2-yl)phenyl)nicotinonitrile 
• 1430217-71-2 N-(2-(4-bromophenyl)-2-methylpropyl)formamide 

Relevant articles and documents

Meta-selective C-H functionalization using a nitrile-based directing group and cleavable Si-tether

A nitrile-based template that enables meta-selective C-H bond functionalization was developed. The template is applicable to a range of substituted arenes and tolerates a variety of functional groups. The directing group uses a silicon atom for attachment

Electrochemical Benzylic C-H Functionalization with Isocyanides

We report the challenging direct carbamoylation or cyanation of benzylic C(sp3)-H bonds with an isocyanide via an electrochemical process giving rise to structures that are encountered in several biologically relevant compounds and drugs. This transformation proceeds under mild conditions without the need for any external oxidant and avoids the necessity to start from a prefunctionalized benzylic substrate or the deployment of the cation pool method. The anodic oxidation of the benzylic position and the subsequent addition of the isocyanide lead to the formation of a C-C bond and to a nitrilium cation that hydrolyzes to yield α-Aryl acetamide derivatives, whereas the elimination of a t-butyl cation delivers α-Aryl acetonitrile derivatives.

Palladium-Catalyzed Distal m-C-H Functionalization of Arylacetic Acid Derivatives

Herein, we present m-C-H olefination on derivatives of phenylacetic acids by tethering with a simple nitrile-based template through palladium catalysis. Notably, the versatility of the method is evaluated with a wide range of phenylacetic acid derivatives for obtaining the meta-olefination products in fair to excellent yields with outstanding selectivities under mild conditions. Significantly, the present strategy is successfully exemplified for the synthesis of drugs/natural product analogues (naproxen, ibuprofen, paracetamol, and cholesterol).

Protein arginine methyltransferase 5 (PRMT5) inhibitor, pharmaceutical products thereof, and methods thereof

The present invention provides a PRMT5 inhibitor of formula (I); R1 is a non-hydrogen monovalent group; W is a direct bond or-NH-; T, U and V are independently from each other selected from C and N; R2 is H or halogen; m is 1 or 2; X is carbon, nitrogen or oxygen; Y is C or N; Z is a direct bond or carbon; R3 is H, a non-hydrogen monovalent group, an oxo group, a divalent spiro-forming group or adivalent bridge-forming group; and n is 1 or 2, and represents a single or double bond. The present invention also provides pharmaceutical products comprising the PRMT5 inhibitor and use thereof in the treatment of proliferative disorders such as cancer, metabolic disorders, hematological disorders, autoimmune diseases and inflammatory diseases.

Cobalt-catalyzed C[sbnd]H activation/C[sbnd]O formation: Synthesis of benzofuranones

Herein, C[sbnd]H activation/C[sbnd]O formation reaction using novel cobalt catalytic system is reported. This reaction was given benzofuranones in moderate to excellent yields at room-temperature under air reaction conditions. The introduced strategy is efficient and low-cost method to synthesized benzofuranones from α,α-disubstitution acetic acid.

INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF

The present invention provides PRMT5 inhibitors of Formula (I), wherein R1 is a non-hydrogen monovalent group; W is a direct bond or -NH-; T, U, and V are independently of each other selected from C and N; R2 is H or a halo; m is 1 or 2; X is a carbon, a nitrogen, or an oxygen; Y is C or N; Z is a direct bond or a carbon; R3 is H, a non-hydrogen monovalent group, an oxo group, a bivalent spiro ring-forming group, or a bivalent bridge-forming group; n is 1 or 2; and Formula (II) stands for a single bond or a double bond. Pharmaceutical products comprising the PRMT5 inhibitors and use thereof in treating proliferative disorders such as cancer, metabolic disorders, blood disorders, autoimmune diseases, and inflammatory diseases are also provided.

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.

ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS

The present invention provides a compound of the Formula (I) below: Wherein R1 is selected from the group consisting of H, CH3, CN, CH2CN, C(CH3)2CN, and F; R2 is selected from the group consisting of H, O(C1-C3alkyl)R5, CH2CN, and CN; R3 is selected from the group consisting of H, OCH3, CN, C(CH3)2CN, and CH2CN; R4 is selected from the group consisting of H and CH3; R5 is selected from the group consisting of H, CN, C(CH3)2CN, OCH3, S(O)2CH3, and C(CH3)2OH; provided that at least one selected from the group consisting of R1, R2, R3 and R4 is H; or a pharmaceutically acceptable salt thereof, methods of treating diabetes using the compound and a process for preparing the compound.